Diabetes Resistant to Subcutaneous Insulin: Effect of Aprotinin

J. C. Pickup, G. Williams, R. W. Bilous, H. Keen, Stephen Colagiuri, Harry Grunstein, M. Berger, R. I. Misbin, W. C. Duckworth, R. E. Offord, P. A. Halban, J. Philippe, Gary R. Freidenberg, Juan F. Sotos, Neil White, Julio V. Santiago, Samuel Cataland, Thomas M. O'dorisio

Research output: Contribution to journalLetterpeer-review

4 Scopus citations


To the Editor: We have reported on a group of exceptionally“brittle”diabetics whose clinical features resemble those of the patients described by Dr. Freidenberg and his colleagues in the August 13 issue.1 All the patients are female; in many the disease is not controlled by doses of more than 100 units of insulin a day, injected or infused subcutaneously. Near normoglycemia is restored by continuous intramuscular infusion of insulin,2 which presumably bypasses a barrier to subcutaneous absorption. Recently, we measured the breakdown of Radio-labeled and native insulin by subcutaneous-tissue biopsy specimens. The rate of insulin degradation in vitro by. . .

Original languageEnglish
Pages (from-to)1413-1414
Number of pages2
JournalNew England Journal of Medicine
Issue number23
StatePublished - Dec 3 1981


Dive into the research topics of 'Diabetes Resistant to Subcutaneous Insulin: Effect of Aprotinin'. Together they form a unique fingerprint.

Cite this